Publications

1. Muwonge R, Basu P, Gheit T, Anantharaman D, Verma Y, Bhatla N, et al.; Indian HPV vaccine study group (2020). Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: a community-based multicentric cohort study. PLoS One. 15(12):e0244242. https://doi.org/10.1371/journal.pone.0244242 PMID:33373380
2. Baussano I, Sayinzoga F, Tshomo U, Tenet V, Vorsters A, Heideman DAM, et al. (2021). Impact of human papillomavirus vaccination, Rwanda and Bhutan. Emerg Infect Dis. 27(1):1–9. https://doi.org/10.3201/eid2701.191364 PMID:33350922
3. Galati L, Combes JD, Gupta P, Sen R, Robitaille A, Brancaccio RN, et al. (2020). Detection of a large spectrum of viral infections in conjunctival premalignant and malignant lesions. Int J Cancer. 147(10):2862–70. https://doi.org/10.1002/ijc.33149 PMID:32525572
4. Mpunga T, Chantal Umulisa M, Tenet V, Rugwizangoga B, Milner DA Jr, Munyanshongore C, et al. (2020). Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. Int J Cancer. 146(6):1514–22. https://doi.org/10.1002/ijc.32491 PMID:31173641
5. Basu P, Muwonge R, Bhatla N, Nene BM, Joshi S, Esmy PO, et al.; Indian HPV vaccine study group (2019). Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years – updated evidence from Indian follow-up cohort study. Papillomavirus Res. 7:75–81. https://doi.org/10.1016/j.pvr.2019.01.004 PMID:30711698
6. Baussano I, Tshomo U, Tenet V, Heideman DAM, Wangden T, Franceschi S, et al. (2020). Prevalence of human papillomavirus and estimation of human papillomavirus vaccine effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018: a cross-sectional study. Ann Intern Med. 173(11):888–94. https://doi.org/10.7326/M20-2849 PMID:32956600
7. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020). Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 8(2):e180–90. https://doi.org/10.1016/S2214-109X(19)30488-7 PMID:31862245
8. Lin C, Slama J, Gonzalez P, Goodman MT, Xia N, Kreimer AR, et al. (2019). Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infect Dis. 19(8):880–91. https://doi.org/10.1016/S1473-3099(19)30164-1 PMID:31204304
9. Bonjour M, Charvat H, Franco EL, Piñeros M, Clifford GM, Bray F, et al. (2021). Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health. S2468-2667(21)00046-3. https://doi.org/10.1016/S2468-2667(21)00046-3 PMID:33864738
10. Combes JD, Clifford GM, Günthard HF, Hauser C, Darling KEA, Valladares P, et al.; Swiss HIV Cohort Study (2020). Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: kinetics and anal cancer risk prediction. Int J Cancer. 147(3):757–65. https://doi.org/10.1002/ijc.32784 PMID:31722114
11. Almonte M, Murillo R, Sánchez GI, González P, Ferrera A, Picconi MA, et al. (2020). Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol. BMJ Open. 10(5):e035796. https://doi.org/10.1136/bmjopen-2019-035796 PMID:32448795
12. Baena A, Agudelo MC, Lopez C, Ramírez AT, Castañeda KM, Bedoya AM, et al.; ASCUS-COL Trial Group (2020). Comparison of immediate colposcopy, repeat conventional cytology and hrHPV testing for the clinical management of ASC-US cytology in routine health services of Medellin, Colombia: the ASCUS-COL trial. Int J Cancer. https://doi.org/10.1002/ijc.33318 PMID:33006400
13. Baena A, De Vuyst H, Mesher D, Kasubi M, Yuma S, Mwaiselage J, et al. (2020). Reproducibility of a rapid human papillomavirus test at different levels of the healthcare system in Tanzania: the AISHA study. Cancer Epidemiol Biomarkers Prev. 29(11):2261–8. https://doi.org/10.1158/1055-9965.EPI-20-0422 PMID:32856600
14. Rodríguez G, García L, Beracochea A, Alonso R, Caserta B, Pérez N, et al. and the ESTAMPA Uruguay Group (2019). Screening of cervical cancer using HPV testing. First results from the Uruguayan public system. Rev Med Urug (Montev). 35(4):267–80. https://doi.org/10.29193/rmu.35.4.3
15. Villain P, Carvalho AL, Lucas E, Mosquera I, Zhang L, Muwonge R, et al.; IARC COVID-19 Impact Study Group (2021). Cross-sectional survey of the impact of the COVID-19 pandemic on cancer screening programs in selected low- and middle-income countries: study from the IARC COVID-19 impact study group. Int J Cancer. 149(1):97–107. https://doi.org/10.1002/ijc.33500 PMID:33533501
16. Escriva-Boulley G, Mandrik O, Préau M, Herrero R, Villain P (2021). Cognitions and behaviours of general practitioners in France regarding HPV vaccination: a theory-based systematic review. Prev Med. 143:106323. https://doi.org/10.1016/j.ypmed.2020.106323 PMID:33171178
17. Pinder LF, Parham GP, Basu P, Muwonge R, Lucas E, Nyambe N, et al. (2020). Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. Lancet Oncol. 21(1):175–84. https://doi.org/10.1016/S1470-2045(19)30635-7 PMID:31734069
18. Poli UR, Muwonge R, Bhoopal T, Lucas E, Basu P (2020). Feasibility, acceptability, and efficacy of a community health worker-driven approach to screen hard-to-reach periurban women using self-sampled HPV detection test in India. JCO Glob Oncol. 6:658–66. https://doi.org/10.1200/GO.20.00061 PMID:32343627
19. Selmouni F, Belakhel L, Sauvaget C, Abousselham L, Lucas E, Muwonge R, et al. (2019). Evaluation of the national cervical cancer screening program in Morocco: achievements and challenges. J Med Screen. 26(3):162–8. https://doi.org/10.1177/0969141318824627 PMID:30651034